We are live on ! Find out more
PRDS

Pardes Biosciences, Inc. Common Stock
PRDS

Delisted

PRDS was delisted on the 30th of August, 2023.

Back to rankings

69 hedge funds and large institutions have $174M invested in Pardes Biosciences, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

1% less capital invested

Capital invested by funds: $176M → $174M (-$1.72M)

8% less funds holding

Funds holding: 75 → 69 (-6)

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

50% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 12

Holders
69
Holders Change
-6
Holders Change %
-8%
% of All Funds
1.2%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
7
Increased
6
Reduced
12
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACA
Arena Capital Advisors
California
+$11.9M
2
6CM
683 Capital Management
New York
+$2.01M
3
PMAM
Picton Mahoney Asset Management
Ontario, Canada
+$1M
4
LC
Littlejohn & Co
Connecticut
+$782K
5
SC
Sculptor Capital
New York
+$723K

Top Sellers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
-$4.35M
2
HM
HealthCor Management
New York
-$3.49M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.48M
4
WRBC
W.R. Berkley Corp
Connecticut
-$1.78M
5
LGM
Logos Global Management
California
-$1.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$16.7M -$424K -42,222 -2%
ACA
2
Arena Capital Advisors
California
$15.1M +$11.9M +1,182,588 +358%
FCM
3
Farallon Capital Management
California
$10M – – –
PHS
4
PFM Health Sciences
California
$10M – – –
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$9.98M – – –
JCM
6
JS Capital Management
New York
$9.98M – – –
RCM
7
RA Capital Management
Massachusetts
$9.98M – – –
SRCM
8
Sage Rock Capital Management
New York
$8.24M – – –
FCMV
9
Foresite Capital Management V
California
$6.01M – – –
MAMNY
10
Marathon Asset Management (New York)
New York
$5.79M – – –
Millennium Management
11
Millennium Management
New York
$5.21M +$477K +47,503 +10%
C
12
Chescapmanager
Maryland
$4.88M – – –
Citadel Advisors
13
Citadel Advisors
Florida
$4.74M -$2.48M -247,455 -34%
GCL
14
Glazer Capital LLC
New York
$4.58M -$4.35M -433,744 -49%
Alyeska Investment Group
15
Alyeska Investment Group
Illinois
$4.49M – – –
Franklin Resources
16
Franklin Resources
California
$4M – – –
HMC
17
Harvard Management Company
Massachusetts
$4M – – –
SCM
18
Suvretta Capital Management
New York
$3.99M – – –
DCM
19
DAFNA Capital Management
California
$2.99M – – –
SC
20
Sculptor Capital
New York
$2.42M +$723K +72,000 +42%
RSCM
21
Rock Springs Capital Management
Maryland
$2.09M – – –
WP
22
Woodline Partners
California
$2.07M – – –
6CM
23
683 Capital Management
New York
$2M +$2.01M +200,288 New
ACM
24
Altium Capital Management
New York
$2M – – –
BCM
25
BlueCrest Capital Management
Jersey
$1.5M – – –
1
2 3 4

PRDS Hedge Fund Activity: Q2 2021 in Review

69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q2 2021, worth a combined $174M — down 0.98% from $176M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of PRDS and 7 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 6 added.

The largest buyer was Arena Capital Advisors, adding an estimated $11.9M. The largest seller was Glazer Capital LLC, cutting an estimated $4.35M.

  • 69 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q2 2021, down from 75 in Q1 2021.
  • Funds reported $174M of Pardes Biosciences, Inc. Common Stock stock for Q2 2021, down 0.98% quarter-over-quarter.
  • 7 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q2 2021 and 13 closed out, a net change of -6 holders.
  • The largest Pardes Biosciences, Inc. Common Stock buyer in Q2 2021 was Arena Capital Advisors, an estimated $11.9M added.
  • The largest Pardes Biosciences, Inc. Common Stock seller in Q2 2021 was Glazer Capital LLC, an estimated $4.35M sold.

Based on aggregated 13F filings for Q2 2021.